The liver diseases known as NASH, the primary cause of transplants of that vital organ, should be on investors’ radars and the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) is the ETF perhaps best situated to capitalize on what could become an almost $10 billion market. SBIO focuses on...